Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia

Neil E. Kay(Mayo Clinic), John C. Byrd(The Ohio State University)

Blood

September 28, 2006

10.1182/blood-2006-07-033274

Cited by 293

Related Papers

Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells

|Blood|2009|140

Comparative Assessment of Clinically Utilized CD20-Directed Antibodies in Chronic Lymphocytic Leukemia Cells Reveals Divergent NK Cell, Monocyte, and Macrophage Properties

|The Journal of Immunology|2013|93

Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines

|Blood|2007|72

Aberrant activation of AXL may drive progression of squamous cell carcinoma in CLL patients: a mechanistic study with clinical implications

|British Journal of Cancer|2024|0